|Table of Contents|

Effects of CBX7 on phenotype maintenance and chemotherapy sensitivity of lung cancer stem cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 15
Page:
2751-2756
Research Field:
Publishing date:

Info

Title:
Effects of CBX7 on phenotype maintenance and chemotherapy sensitivity of lung cancer stem cells
Author(s):
LI Weilei; LI Zhen; ZHUO Yue; ZHANG Lulu; LIANG Dong
Department of Respiratory and Critical Care Medicine,Sanya Central Hospital(Hainan Third People's Hospital),Hainan Sanya 572000,China
Keywords:
chromobox protein homolog 7; lung cancer; cancer stem cells; chemosensitivity; CD44
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.15.001
Abstract:
Objective:To investigate the regulatory effects and potential mechanisms of chromobox protein homolog 7(CBX7) on the phenotype and chemotherapy sensitivity of lung cancer stem cells(LCSCs).Methods:Lung cancer cell lines A549,NCL-H460 and H1299 were cultured,and CD44+ cells were sorted for follow-up experiments.After transfection,CD44+ LCSCs were divided into blank group,negative group(transfected with empty vector) and shCBX7 group(silenced CBX7 expression).Cell count Kit 8(CCK-8) assay and colony formation assay were used to analyze cell proliferation capacity and sensitivity to chemotherapy drugs.The relationship between CBX7 and CD44 was verified using chromatin immunoprecipitation(ChIP) and dual luciferase reporter gene assays.The protein content was detected by Western blot.Results:CD44+LCSCs were successfully enriched from A549,H460 and H1299 cells,and the percentage of CD44+ cells was 97.1%~99.5%.Compared with CD44- cells,the expression of CBX7,CD44,Sox2 and Nanog proteins was higher in CD44+ cells(P＜0.001),CBX7 protein expression was the highest in CD44+ H460 cells(P＜0.05).Therefore,H460 cells were selected for CBX7 silting experiment.After silencing of CBX7 expression in the shCBX7 group,compared with blank group and negative group,the proliferation rate,colony formation ability,the number of tumor balls formed and the protein expressions of CD44,Sox2 and Nanog of CD44+ H460 cells were significantly decreased(P＜0.05).The results of ChIP-qPCR showed that CBX7 could bind to CD44 gene promoter.The overexpression of CBX7 also significantly increased the luciferase activity of CD44 promoter(P＜0.05).In addition,compared with blank groupDDP:(0.98±0.04)μmol/L and DOX(17.5±0.97)μmol/L,the IC50 of DDP(0.87±0.03)μmol/L and DOX(16.3±1.04)μmol/L in CD44+ H460 cells of the negative group were basically the same(P＞0.05).Compared with the negative group,the IC50 of DDP was decreased to(0.08±0.01)μmol/L and DOX was decreased to(0.43±0.03)μmol/L in CD44+H460 cells of the shCBX7 group(P＜0.05).Conclusion:CBX7 can maintain the stemness characteristics of LCSCs and improve the sensitivity of chemotherapy,which has potential research value in the clinical treatment of lung cancer.

References:

[1]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[2]YANG L,SHI P,ZHAO G,et al.Targeting cancer stem cell pathways for cancer therapy［J］.Signal Transduction and Targeted Therapy,2020,5(1):8-43.
[3]OSBORNE JK,MINNA JD.Lung cancer cell of origin:Controversy and clinical translational implications［J］.Cancer Res,2022,82(6):972-973.
[4]PAN Z,ZHANG M,ZHANG F,et al.Single-cell transcriptomics unveils the dedifferentiation mechanism of lung adenocarcinoma stem cells［J］.Int J Mol Sci,2022,24(1):482-498.
[5]DONG GJ,XU JL,QI YR,et al.Critical roles of polycomb repressive complexes in transcription and cancer［J］.Int J Mol Sci,2022,23(17):9574-9606.
[6]LI J,OUYANG T,LI M,et al.CBX7 is dualistic in cancer progression based on its function and molecular interactions［J］.Front Genet,2021,12:1-12.
[7] 舒垠,王伯庆,唐津天,等.CBX7与恶性肿瘤关系研究进展［J］.医学综述,2020,26(07):1319-1324. SHU Y,WANG BQ,TANG JT,et al.Research progress on the relationship between CBX7 and malignant tumors［J］.Medical Recapitulate,2020,26(07):1319-1324.
[8]LIU T,ZHANG X,YANG H,et al.High-mobility group A1(HMGA1) gene expressions in various colorectal cancer cell lines and correlation with prognosis［J］.Transl Cancer Res,2020,9(2):763-773.
[9] 杨婷,冉宇靓.靶向肿瘤干细胞治疗肿瘤［J］.中国肿瘤生物治疗杂志,2021,28(07):651-658. YANG T,RAN YL.Targeting tumor stem cells for tumor therapy［J］.Chinese Journal of Cancer Biotherapy,2021,28(07):651-658.
[10]LI J,XU Z,ZHOU L,et al.Expression profile and prognostic values of Chromobox family members in human glioblastoma［J］.Aging(Albany NY),2022,14(4):1910-1931.
[11]LI X,GOU J,LI H,et al.Bioinformatic analysis of the expression and prognostic value of chromobox family proteins in human breast cancer［J］.Sci Rep,2020,10(1):1-11.
[12]HUANG Z,YAN Y,ZHU Z,et al.CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling［J］.Cell Death Dis,2021,12(6):537-552.
[13]HASSN MESRATI M,SYAFRUDDIN SE,MOHTAR MA,et al.CD44:A multifunctional mediator of cancer progression［J］.Biomolecules,2021,11(12):1850-1881.
[14]ZHANG S,ZHU N,LI HF,et al.The lipid rafts in cancer stem cell:a target to eradicate cancer［J］.Stem Cell Res Ther,2022,13(1):432-446.
[15]DZOBO K,SINKALA M.Cancer stem cell marker CD44 plays multiple key roles in human cancers:Immune suppression/evasion,drug resistance,epithelial-mesenchymal transition and metastasis［J］.OMICS,2021,25(5):313-332.
[16]魏永健，吴永娜，张磊,等.CD44与消化系统肿瘤的关系及靶向治疗研究进展 ［J］.现代肿瘤医学，2021,29(06):1055-1058. WEI YJ，WU YN，ZHANG L,et al.Research progress on CD44 in digestive system tumors and targeted therapy ［J］.Modern Oncology,2021,29(06):1055-1058.
[17]詹盼盼,舒雄,陈梦.微小RNA-195抑制CD44+胃癌干细胞的干性特征和侵袭能力［J］.江苏医药,2021,47(05):437-442,446. ZHAN PP,SHU X,CHEN M.MiRNA-195 inhibits the stemness and invasion ability of CD44+ gastric cancer stem cells［J］.Jiangsu Medical Journal,2021,47(05):437-442,446.
[18]YU X,MUNOZ-SAGREDO L,STREULE K,et al.CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues［J］.Blood,2021,138(12):1067-1080.
[19]GERARDO-RAMREZ M,KEGGENHOFF FL,GIAM V,et al.CD44 contributes to the regulation of MDR1 protein and doxorubicin chemoresistance in osteosarcoma［J］.Int J Mol Sci,2022,23(15):8616-8635.
[20]ZHAO Y,ZHENG R,CHEN J,et al.CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer(NSCLC)［J］.Cancer Cell Int,2020,20:1-12.
[21]GUO B,WEI J,WANG J,et al.CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy［J］.Acta Biomater,2022,145:200-209.

Memo

Memo:
海南省自然科学基金（编号：821RC735)
Last Update: 2023-06-30